Kymera Therapeutics Inc (NASDAQ: KYMR) is 10.02% higher on its value in year-to-date trading and has touched a low of $19.44 and a high of $53.27 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KYMR stock was last observed hovering at around $43.58 in the last trading session, with the day’s gains setting it 0.68%.
Currently trading at $44.26, the stock is 37.77% and 48.35% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.14 million and changing 1.56% at the moment leaves the stock 12.12% off its SMA200. KYMR registered 37.84% gain for a year compared to 6-month loss of -5.53%. The firm has a 50-day simple moving average (SMA 50) of $29.8341 and a 200-day simple moving average (SMA200) of $39.474575.
The stock witnessed a 31.80% gain in the last 1 month and extending the period to 3 months gives it a 39.62%, and is 53.68% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 18.73% over the week and 8.97% over the month.
Kymera Therapeutics Inc (KYMR) has around 188 employees, a market worth around $2.88B and $58.88M in sales. Profit margin for the company is -409.07%. Distance from 52-week low is 127.62% and -16.91% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.03%).
with sales reaching $17.37M over the same period.The EPS is expected to shrink by -15.81% this year, but quarterly earnings will post 59.97% year-over-year. Quarterly sales are estimated to shrink -32.28% in year-over-year returns.
250.0 institutions hold shares in Kymera Therapeutics Inc (KYMR), with institutional investors hold 114.81% of the company’s shares. The shares outstanding are 65.11M, and float is at 53.22M with Short Float at 13.14%. Institutions hold 111.72% of the Float.
The top institutional shareholder in the company is PRICE T ROWE ASSOCIATES INC /MD/ with over 6.39 million shares valued at $$190.76 million. The investor’s holdings represent 8.7472 of the KYMR Shares outstanding. As of 2024-06-30, the second largest holder is BAKER BROS. ADVISORS LP with 6.0 million shares valued at $$178.98 million to account for 8.2069 of the shares outstanding. The other top investors are ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC which holds 5.35 million shares representing 7.3234 and valued at over $$159.71 million, while BVF INC/IL holds 7.0652 of the shares totaling 5.16 million with a market value of $$154.08 million.
Kymera Therapeutics Inc (KYMR) Insider Activity
The most recent transaction is an insider sale by Esposito Pamela, the company’s Director. SEC filings show that Esposito Pamela sold 5,000 shares of the company’s common stock on Jun 03 ’25 at a price of $49.04 per share for a total of $0.25 million. Following the sale, the insider now owns 0.0 shares.
Kymera Therapeutics Inc disclosed in a document filed with the SEC on Jun 03 ’25 that Ridloff Elena (Director) sold a total of 12,000 shares of the company’s common stock. The trade occurred on Jun 03 ’25 and was made at $46.10 per share for $0.55 million. Following the transaction, the insider now directly holds 0.0 shares of the KYMR stock.
Still, SEC filings show that on Jun 03 ’25, Mainolfi Nello (Chief Executive Officer) disposed off 30,000 shares at an average price of $49.00 for $1.47 million. The insider now directly holds 660,482 shares of Kymera Therapeutics Inc (KYMR).
